The Effects of Sports Drinks on Urinary Lithogenicity

This study has been completed.
Sponsor:
Information provided by:
VA New York Harbor Healthcare System
ClinicalTrials.gov Identifier:
NCT00381277
First received: September 26, 2006
Last updated: February 18, 2011
Last verified: February 2011
  Purpose

The effect of sports drinks on the tendency to form kidney stones has not been assessed. Patients will drink 1 liter a day of 2 sports drinks and collect urine to determine changes in urine chemistry that may decrease the risk of forming stones.


Condition Intervention
Urolithiasis
Drug: Gatorade
Drug: Performance

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The Effects of Sports Drinks on Urinary Lithogenicity

Resource links provided by NLM:


Further study details as provided by VA New York Harbor Healthcare System:

Primary Outcome Measures:
  • Urinary supersaturation of calcium oxalate
  • Urinary citrate excretion
  • Urinary calcium excretion
  • Urinary sodium excretion

Estimated Enrollment: 10
Study Start Date: March 2006
Study Completion Date: September 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Participants will drink 1 liter of water each day for one week in the control period, then 1 liter of sports drink each day for one week during the experimental period. Urine collections will be performed during both periods. Diet will be chosen by participants and a food diary will be kept so that participants can replicate diet during the urine collections.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • age 18-80 years old
  • men and women
  • able to sign informed consent

Exclusion Criteria:

  • history of kidney stones
  • bone disease
  • parathyroid disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00381277

Locations
United States, New York
New York Harbor VAMC
New York, New York, United States, 10010
Sponsors and Collaborators
VA New York Harbor Healthcare System
Investigators
Study Director: David S Goldfarb, MD New York Harbor VAMC
  More Information

Additional Information:
No publications provided

Responsible Party: David S Goldfarb MD, New York Harbor VA Medical Center
ClinicalTrials.gov Identifier: NCT00381277     History of Changes
Other Study ID Numbers: DG-1
Study First Received: September 26, 2006
Last Updated: February 18, 2011
Health Authority: United States: Institutional Review Board
United States: Federal Government

Keywords provided by VA New York Harbor Healthcare System:
nephrolithiasis
citrate
oxalate

Additional relevant MeSH terms:
Urolithiasis
Urologic Diseases

ClinicalTrials.gov processed this record on July 31, 2014